BSI-045B has demonstrated safety and efficacy for moderate to severe atopic dermatitis. Credit: Stock-Asso/Shutterstock. Aclaris Therapeutics has secured an exclusive licence from Biosion for the
The programme utilises Intellia’s CRISPR-based gene editing platform and DNA-writing technology. Credit: Natali _ Mis/Shutterstock. ReCode Therapeutics is set to secure up to $15m in
AstraZeneca is exploring Tagrisso in the NeoADAURA Phase III trial. Credit: © AstraZeneca. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)
Afqlir is set to combat blindness associated with neovascular age-related macular degeneration. Credit: SG SHOT/Shutterstock. The European Commission (EC) has granted marketing authorisation for Sandoz‘s
The approval marks the therapy as the first and only menin inhibitor for treating patients one year and older with relapsed or refractory acute leukaemia
Opdivo and Yervoy combination is used for the first-line treatment of adult patients with colorectal cancer. Credit: Jo Panuwat D/Shutterstock. The European Medicines Agency’s (EMA)
Danziten is set to be available soon via Biologics by McKesson and Limited Specialty Distribution. Credit: Motortion Films via Shutterstock. The US Food and Drug
The agreement is set to conclude in Q4 2024. Credit: Merck & Co. MSD has secured an exclusive worldwide license from LaNova Medicines for developing,
Sarclisa has been approved in over 50 countries for certain adult patients with relapsed or refractory MM. Credit: luchschenF via Shutterstock. The European Medicines Agency’s
AADC deficiency is a genetic disorder that severely impairs motor function by preventing dopamine synthesis. Credit: Gatot Adri via Shutterstock. The US Food and Drug